FABP4-Binding Compounds Modulating Adipocyte Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to targeting fatty acid binding protein 4 (FABP4) for treating metabolic and inflammatory diseases, such as type-2 diabetes and cardiovascular disease, are incomplete as they do not provide a comprehensive solution for modulating adipocyte metabolism to enhance glucose utilization.
Innovation Solution
Development of a novel class of compounds that bind to FABP4, specifically designed to modulate adipocyte metabolism by enhancing glucose utilization, as represented by compounds of Formula (I), (II), and (III), which can be used in pharmaceutical compositions for treating various disorders associated with FABP4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If FABP4 is targeted to treat metabolic diseases, then glucose utilization in adipocytes is improved, but current approaches do not provide comprehensive modulation of adipocyte metabolism
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I, II, III) that bind to FABP4 with optimized affinity and selectivity. The compounds feature variable substituents (R1-R8, W1-W4, Z1-Z5) that can be adjusted to modulate different metabolic parameters including glucose uptake, lipid storage, and inflammatory responses, providing comprehensive metabolism modulation while improving glucose utilization.
2Reliability
If FABP4 expression is reduced genetically, then protection from hyperglycemia and insulin-resistance is achieved, but this approach is not translatable to pharmacological treatment
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to FABP4 and modulate its function without requiring genetic modification. These compounds act as pharmacological mediators that replicate the protective effects of FABP4 knockout (reduced hyperglycemia and insulin-resistance) while being suitable for clinical administration, thus bridging the gap between genetic findings and pharmaceutical treatment.
3Productivity
If FABP4 is inhibited to improve glucose consumption, then adipocyte metabolism is enhanced, but existing compounds do not provide sufficient selectivity and efficacy
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups and spatial arrangements (e.g., aromatic rings, heterocyclic structures, specific substituent positions) that interact with particular regions of the FABP4 binding pocket. This localized molecular design enhances selectivity for FABP4 over other FABP isoforms and optimizes efficacy in modulating glucose consumption and metabolic pathways in adipocytes.
Data Source
AI summary
A novel class of compounds according to Formula I, II, or III, wherein W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments that bind to fatty acid binding protein FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.